These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 8808455)

  • 1. Clinical heparin coated cardiopulmonary bypass: reduction of systemic heparin requirements for redo cardiac surgery.
    Ladowski JS; Schatzlein MH; Peterson AC; Deschner WP; Matheis R; Ellenwood M; Bach J; Moldovan L; McKamey D
    ASAIO J; 1996; 42(1):34-6. PubMed ID: 8808455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deleterious effects of cardiopulmonary bypass on early graft function after single lung allotransplantation: evaluation of a heparin-coated bypass circuit.
    Francalancia NA; Aeba R; Yousem SA; Griffith BP; Marrone GC
    J Heart Lung Transplant; 1994; 13(3):498-507. PubMed ID: 8061027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heparinized cardiopulmonary bypass and full heparin dose marginally improve clinical performance.
    Ovrum E; Am Holen E; Tangen G; Ringdal MA
    Ann Thorac Surg; 1996 Oct; 62(4):1128-33. PubMed ID: 8823101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heparin-coated versus uncoated extracorporeal circuit in patients undergoing coronary artery bypass graft surgery.
    Oliver WC; Nuttall GA; Ereth MH; Santrach PJ; Buda DA; Schaff HV
    J Cardiothorac Vasc Anesth; 2003 Apr; 17(2):165-70. PubMed ID: 12698396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of activated coagulation time-based techniques for anticoagulation during cardiac surgery with cardiopulmonary bypass.
    Slight RD; Buell R; Nzewi OC; McClelland DB; Mankad PS
    J Cardiothorac Vasc Anesth; 2008 Feb; 22(1):47-52. PubMed ID: 18249330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction and elimination of systemic heparinization during cardiopulmonary bypass.
    von Segesser LK; Weiss BM; Garcia E; von Felten A; Turina MI
    J Thorac Cardiovasc Surg; 1992 Apr; 103(4):790-8; discussion 798-9. PubMed ID: 1548923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of cell saver autologous blood transfusion on blood loss and homologous blood transfusion requirements in patients undergoing cardiac surgery on- versus off-cardiopulmonary bypass: a randomised trial.
    Niranjan G; Asimakopoulos G; Karagounis A; Cockerill G; Thompson M; Chandrasekaran V
    Eur J Cardiothorac Surg; 2006 Aug; 30(2):271-7. PubMed ID: 16829083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biocompatibility reflected by haemostasis variables during cardiopulmonary bypass using heparin-coated circuits.
    Borowiec J; Bagge L; Saldeen T; Thelin S
    Thorac Cardiovasc Surg; 1997 Aug; 45(4):163-7. PubMed ID: 9323816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biocompatibility of heparin-coated cardiopulmonary bypass circuits in coronary patients with left ventricular dysfunction is superior to PMEA-coated circuits.
    Kutay V; Noyan T; Ozcan S; Melek Y; Ekim H; Yakut C
    J Card Surg; 2006; 21(6):572-7. PubMed ID: 17073955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The evaluation of the bio-compatibility and the clinical usefulness of heparin-coated cardiopulmonary bypass circuits].
    Yamanaka J; Takeuchi Y; Torii S; Gomi A; Nakatani H; Kohno K
    Nihon Kyobu Geka Gakkai Zasshi; 1996 Jan; 44(1):47-53. PubMed ID: 8683171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and biomaterial evaluation of hyaluronan-based heparin-bonded extracorporeal circuits with reduced versus full systemic anticoagulation in reoperation for coronary revascularization.
    Gunaydin S; Farsak B; McCusker K; Vijay V; Sari T; Onur MA; Gurpinar A; Zorlutuna Y
    J Cardiovasc Med (Hagerstown); 2009 Feb; 10(2):135-42. PubMed ID: 19377380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heparin-coated circuits reduce complement activation and inflammatory response to cardiopulmonary bypass.
    Tamim M; Demircin M; Guvener M; Peker O; Yilmaz M
    Panminerva Med; 1999 Sep; 41(3):193-8. PubMed ID: 10568115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring activated clotting time for combined heparin and aprotinin application: in vivo evaluation of a new aprotinin-insensitive test using Sonoclot.
    Ganter MT; Monn A; Tavakoli R; Genoni M; Klaghofer R; Furrer L; Honegger H; Hofer CK
    Eur J Cardiothorac Surg; 2006 Aug; 30(2):278-84. PubMed ID: 16828293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of two heparin-coated extracorporeal circuits with reduced systemic anticoagulation in routine coronary artery bypass operations.
    Ovrum E; Tangen G; Oystese R; Ringdal MA; Istad R
    J Thorac Cardiovasc Surg; 2001 Feb; 121(2):324-30. PubMed ID: 11174738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of heparin-coated circuits with full heparin dose strategy.
    Sinci V; Kalaycioglu S; Gunaydin S; Imren Y; Gokgoz L; Soncul H; Ersoz A
    Ann Thorac Cardiovasc Surg; 1999 Jun; 5(3):156-63. PubMed ID: 10413761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical use of heparin-coated cardiopulmonary bypass in coronary artery bypass grafting.
    Mirow N; Minami K; Kleikamp G; Tenderich G; Puhlmann T; Körfer R
    Thorac Cardiovasc Surg; 2001 Jun; 49(3):131-6. PubMed ID: 11432470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Redo coronary artery bypass grafting with and without cardiopulmonary bypass in the elderly.
    Czerny M; Zimpfer D; Kilo J; Gottardi R; Wolner E; Grimm M
    Heart Surg Forum; 2003; 6(4):210-5. PubMed ID: 12928202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation of a thrombin inhibitor peptide as an alternative to heparin in cardiopulmonary bypass surgery.
    Chomiak PN; Walenga JM; Koza MJ; Reilly TM; Turlapathy P; Pifarre R
    Circulation; 1993 Nov; 88(5 Pt 2):II407-12. PubMed ID: 7993389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Preoperative autologous blood donation with cardiac surgery].
    Yoda M; Nonoyama M; Shimakura T; Morishita A; Takasaki T
    Kyobu Geka; 2003 Jun; 56(6):479-82. PubMed ID: 12795154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
    Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
    Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.